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Deep‑learned time‑signal 
intensity pattern analysis using 
an autoencoder captures magnetic 
resonance perfusion heterogeneity 
for brain tumor differentiation
Ji Eun Park1, Ho Sung Kim1*, Junkyu Lee2, E.‑Nae Cheong2, Ilah Shin3, Sung Soo Ahn3 & 
Woo Hyun Shim1,2
Current image processing methods for dynamic susceptibility contrast (DSC) magnetic resonance 
imaging (MRI) do not capture complex dynamic information of time‑signal intensity curves. We 
investigated whether an autoencoder‑based pattern analysis of DSC MRI captured representative 
temporal features that improves tissue characterization and tumor diagnosis in a multicenter setting. 
The autoencoder was applied to the time‑signal intensity curves to obtain representative temporal 
patterns, which were subsequently learned by a convolutional neural network. This network was 
trained with 216 preoperative DSC MRI acquisitions and validated using external data (n = 43) 
collected with different DSC acquisition protocols. The autoencoder applied to time‑signal intensity 
curves and clustering obtained nine representative clusters of temporal patterns, which accurately 
identified tumor and non‑tumoral tissues. The dominant clusters of temporal patterns distinguished 
primary central nervous system lymphoma (PCNSL) from glioblastoma (AUC 0.89) and metastasis 
from glioblastoma (AUC 0.95). The autoencoder captured DSC time‑signal intensity patterns that 
improved identification of tumoral tissues and differentiation of tumor type and was generalizable 
across centers.
Dynamic susceptibility contrast (DSC) MRI is the most commonly used perfusion technique in clinical  practice1 
and in clinical  trial2, 3 for evaluation of brain tumor vascularity. Much of the discussion of DSC MRI has focused 
on measurements using relative cerebral blood volume (rCBV)4–7, and other parameters of relative  recirculation8, 9 
and vascular  permeability10–12. However, these techniques are limited to fully capture dynamic information that 
DSC MRI retains. Every voxel in tumors exhibits different series of signal intensities according to time, and analy-
sis of stationary and one-dimensional (scalar) values do not allow for a complete characterization of dynamic 
perfusion information. Also, model-based calculation of rCBV and relative recirculation requires sophisticated 
assumption and introduces potential sources of  variances8, 13, 14 from different pulse sequence parameters, contrast 
media, model assumption from different hospital  setting15. Unsupervised learning of time-series data, on the 
other hand, has a great potential to learn complex time-signal intensity data in DSC  MRI16, 17, which can provide 
additional information that cannot be captured with current perfusion MRI processing.
Time-signal intensity patterns can be learned by an autoencoder neural network for high-dimensional time-
series  data16. This method uses an unsupervised learning algorithm to learn a compressed representation of the 
input data. The autoencoder has an encoder-decoder architecture that removes unnecessary noise and generates 
representations from a low-dimensional latent space by stacking multiple non-linear  transformations16, 18. This 
architecture enables the modeling of complex non-linear functions, unlike linear transformations in principal 
component  analysis19. Also, the low-dimensional latent space in the autoencoder can encode the most important 
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features of the input data, which can then be used in data visualization and become a representation for a super-
vised learning model.
We hypothesized that the autoencoder would capture temporal patterns from DSC MRI data that are not 
accessible with current perfusion MRI processing, whichwould yield high diagnostic values in brain tumors with 
clinical relevance. We investigated whether autoencoder-derived pattern analysis of DSC MRI data captured 
representative temporal features and augmented tumor characterization in terms of heterogeneity and across 
multiple centers.
Methods
Patients. This retrospective study was approved by the Institutional Review Board of the Asan Medical 
Center (approval no. 2019-0594), and all methods were carried out in accordance with the institution’s guide-
lines and regulations. The requirement for informed consent was formally waived by the approving committee. 
The electronic database of the Department of Radiology at the University of Ulsan, College of Medicine was 
searched and records for patients between September 2013 and March 2019 were retrospectively reviewed. In 
total, 389 patients were identified. The inclusion process is shown in Fig. 1. The inclusion criteria were patients 
with a single contrast-enhancing tumor revealed by preoperative anatomic MRI and DSC MRI. Exclusion cri-
teria were as follows: (1) no pathologic confirmation; (2) patients who had a prior tumor treated with surgery, 
radiation, or chemotherapy; (3) multiple contrast-enhancing tumors; and (4) poor image quality. Twenty-three 
patients were excluded because of prior resection or therapy, and 30 patients were excluded because of multiple 
tumors. In addition, 50 patients were excluded because DSC MRI data were not available, and 10 patients were 
excluded because of poor image quality caused by artifacts. After applying the exclusion criteria, there were 276 
remaining patients (mean age 60.4 years; male: female ratio 152: 124). Of these patients, 137 had glioblastoma, 
80 had lymphoma, and 59 had brain metastasis. The autoencoder was developed using training, and internal 
validation set was formed based on a temporal split of the institutional data obtained in September 2013 and July 
2018. The training set included 216 patients (glioblastoma:PCNSL:metastasis = 109:58:49). The internal valida-
tion set included 60 patients (glioblastoma:PCNSL:metastasis = 28:22:10).
To test the generalizability and performance of the  algorithm20, an external validation set consisting of 43 
patients from another tertiary medical center (Severance Hospital, Seoul, Korea) was included. A total of 28 
patients with pathologically confirmed glioblastoma and 15 patients with PCNSL were used for external valida-
tion of the model.
Imaging data. All MRI sessions on enrolled patients at both institutions were performed on a 3 T unit 
(Achieva or Ingenia; Philips Medical Systems, Best, Netherlands) equipped with a 32-channel head coil. The 
Figure 1.  The inclusion process of the study patients.
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brain-tumor imaging protocol included the following sequences: T2-weighted, fluid-attenuated inversion recov-
ery (FLAIR), T1-weighted, diffusion-weighted, contrast-enhanced T1-weighted (CE-T1WI), and DSC perfu-
sion MRI. The DSC data were collected using T2*-weighted gradient echo-planar images.
The DSC MRI protocol used for the training and internal validation sets began with a preload of 0.1 mmol/
kg gadoterate meglumine (Dotarem; Guerbet), was given before the dynamic bolus. Then, the dynamic bolus 
was administered as a standard dose of 0.1 mmol/kg gadoterate meglumine delivered at a rate of 4 mL/s by an 
MRI-compatible power injector (Spectris; Medrad). The bolus of contrast material was followed by a 20 mL bolus 
of saline, which was injected at the same rate. The pulse sequence parameters included the following: repetition 
time (TR)/echo time (TE), 1724/40 ms; flip angle, 35°; field of view (FOV), 240 mm; slice thickness/gap, 5/2 mm; 
matrix, 128 × 128; total acquisition time, 1 min and 50 s. Dynamic acquisition was performed with a temporal 
resolution of 1.7 s, and 60 dynamics were acquired. Each timepoint included 20 slices, covering the whole brain 
in the same orientation as that used for the conventional sequences.
In the external validation set, DSC images were also obtained with a preload of gadobutrol (0.1 mmol/
kg Gadovist, Bayer Schering Pharma) given before the dynamic bolus. Then, a 0.1 mmol/kg dynamic bolus 
of gadobutrol was injected at a rate of 4 mL/s, followed by a bolus injection of saline (total 20 mL at 4 mL/s). 
The pulse sequence parameters included the following: TR/TE, 1600/30 ms; flip angle, 40°; FOV, 220 mm; slice 
thickness/gap, 5/1.8 mm; 128 × 128 matrix. The dynamic acquisition was performed with a temporal resolution 
of 1.6 s, and 60 dynamics were acquired.
Labeling of brain tissue and brain tumor. The CE-T1WI and FLAIR images were co-registered to the 
DSC images to define brain regions. The co-registration process was performed in Statistical Parametric Map-
ping (SPM12) and used affine transformations with six degrees of freedom and 4th degree B-spline interpola-
tion. The probability template matching in SPM12 was also used to segment and label brain  regions21 into gray 
matter, white matter, and cerebral spinal fluid (CSF). Non-brain tissues were excluded in this step.
Tumor segmentation was performed semi-automatically by a neuroradiologist (2 years of experience in neuro-
oncological imaging) using the CE-T1WI and FLAIR data. Necrosis and the contrast-enhancing solid portion 
were selected on the 3D CE-T1WI. The FLAIR images were used to select edema/non-enhancing tumor por-
tions using a segmentation threshold and region-growing segmentation algorithm that was implemented using 
MITK software (www.mitk.org; German Cancer Research Center, Heidelberg, Germany)22. All segmented images 
were checked by an expert radiologist (6 years of experience in neuro-oncological imaging). For glioblastoma 
cases, contrast-enhancing tumors, non-enhancing tumors, and necrosis were all segmented. For lymphoma and 
metastasis cases, contrast-enhancing tumors were segmented. In total, there were nine pre-defined different tissue 
types in the co-registered DSC images: three types of contrast-enhancing tumors (glioblastoma, lymphoma, and 
metastasis), non-enhancing tumors, edema, gray matter, white matter, CSF, and necrosis.
Calculation of autoencoder representations. DSC time-signal intensity curves were calculated and 
the scale was normalized based on the median value of white matter for each brain. Then, outliers were removed 
from the time-series data by excluding data that were ± 1 standard deviation outside the mean signal. After this 
process, DSC time-signal intensity curves included for each patient were approximately 4.6 × 104 time-signal 
intensity curves (mean 46,342, standard deviation, 12,765).
Representations from high-dimensional DSC time-signal intensity data were trained using a single-layer 
sparse autoencoder.
Each autoencoder consisted of two parts: the encoder and the decoder (Supplementary Fig. S1). Each time-
signal intensity curve of 60 time points formed a 60-element input vector. The encoder was a one-dimensional 
convolutional layer using a rectified linear unit (ReLu) and a one-dimensional max pooling layer. The kernel size 
of the convolution layer was 2 and the filter size 32; the output size of the convolution layer was kept the same by 
applying the padding parameter as ‘same’. A dropout layer with 0.7 probability was introduced after the batch-
normalization layer to reduce overfitting. The number of latent spaces was set to five. The decoder reconstructed 
data with the same size (60 time points) as the input data through two fully-connected layers. Mean squared 
error was used to calculate the loss between the output and input signal. The learning rate was 1 × 10–5 and the 
batch size for training was set to 10,000.
The autoencoder-derived representations captured the highest variance from DSC time-signal intensity data 
and all subjects under the constraint that variance was uncorrelated with each representation. These representa-
tions thus reflected various aspects of the DSC time-signal intensity curve patterns including baseline signal, 
depth of signal decrease, slopes of signal decrease and recovery, and percentage recovery. We trained the num-
ber of representations that accounted for more than 99% of the overall variance in the perfusion signal across 
individuals.
Then, k-means clustering was applied to the autoencoder-derived representations. A total of nine clusters 
were identified from the autoencoder representations, and the autoencoder representations in the latent space 
were decoded into decoded time-signal intensity curves representing temporal patterns. The nine clusters of 
decoded time-signal intensity curves (temporal patterns) were used to characterize the nine pre-defined tissue 
types, which consisted of three types of contrast-enhancing tumors, non-enhancing tumors, edema, gray matter, 
white matter, CSF, and necrosis. For this, information on the anatomic position using an x–y-z coordinate sys-
tem was obtained from the decoded time-signal intensity curves and subsequently used for anatomic mapping. 
The nine clusters of temporal patterns were mapped onto anatomic images for visualization and to distinguish 
tumoral regions from normal-appearing brain tissue.
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Supervised learning using decoded time‑signal intensity curves in brain tumor. Whether the 
decoded time-signal intensity patterns provided clinically relevant information for brain tumor characterization 
and differential diagnosis in terms of intratumoral perfusion heterogeneity was investigated. For this analysis, 
a deep convolutional neural network (CNN) was used to learn the representative time-signal intensity patterns 
characterizing specific pathologic tumor types. Because there was no voxel-based confirmation of tumor and 
non-tumor tissue, it was assumed that two dominant patterns exhibiting the highest proportions within the con-
trast-enhancing lesion represented specific pathologic tumor types. Within the CEL, the proportion of each clus-
ter was calculated. Among them, two clusters with the highest proportions were selected as ‘dominant clusters’ 
and the decoded time-signal intensity curves from the two dominant clusters were subsequently used as input 
for CNN. Thus, the input for CNN was all 1 × 60 input vectors obtained from the decoded time-signal intensity 
curves from the two dominant clusters. A CNN was designed with 3 convolutional blocks, 2 fully connected 
layers, and softmax layer for classification. The input data size was 60-element input vector from 60 time points 
of each time-signal intensity curve. The convolutional blocks consisted of one-dimensional convolutional layer 
combined by a max-pooling operation, batch-normalization, and a drop-out layer (Supplementary Fig. S2). The 
kernel size of convolution layer was 2 and the number of feature maps was 32, and the output size of convolution 
layer was kept same by applying padding parameter as ‘same’. Max pooling layer down-sampled the representa-
tions by 50% for each repetition and batch-normalization was introduced, followed by drop-out layer with 0.7 
of probability. Two fully-connected layers using ReLU were applied to make the same size representatives with 
the number of classes and then softmax layer was applied to convert these representative values as probabilities. 
Softmax-cross-entropy cost function was used to calculate the loss between labels and predictions. The learning 
rate was 1 × 10–8 and the batch size for training was set to 1,000. The deep-learning architecture was implemented 
by using the Tensorflow1.14.
Statistical analysis. Student’s t-tests and the Chi-square tests were used to assess differences in demo-
graphic data and the prevalence of each classification category between the training and validation sets.
Tumor differentiation. To test diagnostic performance, the area under the curve (AUC), from receiver oper-
ating characteristic curve analysis, was calculated. The optimal thresholds of the AUCs were determined by 
maximizing the sum of the sensitivity and specificity values calculated for differentiation of brain tumors. To 
differentiate PCNSL from glioblastoma and brain metastasis from glioblastoma, the diagnostic performance 
was calculated with glioblastoma as a reference diagnosis. The accuracy, sensitivity, and specificity of correctly 
diagnosing glioblastoma from other tumors were defined as
where TP is a true positive, TN a true negative, FP a false positive, and FN a false negative.
Comparison to conventional approach. The diagnostic performance of the autoencoder analysis of DSC time-
signal intensity patterns was compared with that of the conventional approach using mean rCBV.
P values less than 0.05 were considered to indicate significant differences. Statistical analyses were performed 
using R statistical software (version 3.6.3, R Core Team, Vienna, Austria).
Results
Patient baseline demographics and clinical characteristics are summarized in Table 1. The training set included 
216 patients (109 glioblastoma, 58 PCNSL, and 49 metastasis), and the internal validation set had 60 patients 
(28 glioblastoma, 22 PCNSL, and 10 metastasis). The external validation set had 43 patients (28 glioblastomas 
and 15 PCNSLs). There were no significant differences in sex across the sets or in sex among patients in either 
the training or validation sets.
Encoded representations and clusters of temporal patterns for tissue characterization. The 
extraction of autoencoder-derived representations, cluster visualization, and decoded time-signal intensity pat-
terns are shown in Fig. 2.
Accuracy =
TP+ TN







Table 1.  Patient baseline demographic and clinical characteristics. P values apply to the differences among 








P valueGlioblastoma PCNSL Metastasis Glioblastoma PCNSL Metastasis Glioblastoma PCNSL
Patients (N) 109 58 49 28 22 10 28 15
Number of females (N) 42 33 20 0.52 11 13 5 0.56 13 7 0.53
Age (years old) 58.1 ± 13.5 62.3 ± 11.7 61.5 ± 12.0 0.29 57.58 ± 7.96 62.7 ± 11.9 61.0 ± 11.3 0.38 57.8 ± 10.5 65.3 ± 10.9 0.06
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Figure 2.  Extracting autoencoder features from dynamic susceptibility contrast (DSC) imaging. (a) DSC time-
signal intensity curves were reduced using an autoencoder. (b) The autoencoder features were clustered into 
nine representative tissue types including contrast-enhancing lesions (CEL) (e.g., glioblastoma, lymphoma, and 
metastasis), non-enhancing tumor portions, edema, necrosis, gray matter, white matter, and cerebral spinal fluid 
(CSF). (c) The clusters were spatially mapped within the CEL and decoded time-signal intensity curves were 
clustered into nine different clusters. (d) A convolutional neural network (CNN) was trained with two dominant 
clusters of decoded time-signal intensity curves and tested for tumor differentiation. The figure was drawn using 
Matlab (version R2017b, Mathworks, Natick, MA) and extra permission for drawing figures was not required.
Table 2.  Brain tissue characterization based on frequency of patterns. The numbers in the cells are percentages 
with mean ± standard deviation and the numbers in the parenthesis are minimum to maximum. Necrosis 
is defined in glioblastoma and metastasis. CEL contrast-enhancing lesion. PCNSL primary central nervous 
system lymphoma.
Dominant pattern Pattern 0 Pattern 1 Pattern 2 Pattern 3 Pattern 4 Pattern 5 Pattern 6 Pattern 7 Pattern 8
CEL in glio-
blastoma 5 and 3
13.5 ± 1.3 
(0–57.2)
0.3 ± 0.1 (0 
-44.9)
14.3 ± 0.1 
(0–45.7)
26.7 ± 0.2 (0 
-85.0)
4.6 ± 0.0 
(0–18.1)
32.6 ± 0.1 
(0–49.1)
1.4 ± 0.0 
(0–41.4)
2.3 ± 0.0 
(0–26.9)
4.3 ± 0.2 
(0–99.2)
CEL in PCNSL 5 and 3 15.0 ± 0.2 (0–54.3)
0.1 ± 0.1 
(0–59.1)
6.6 ± 0.2 
(0–100)
27.7 ± 0.4 
(0–100) 5.0 ± 0.1 (0–90)
37.0 ± 0.4 
(0–100)
1.9 ± 0.1 
(0–41.1)
1.5 ± 0.1 
(0–73.3)
5.2 ± 0.2 
(0–100)
CEL in metas-
tasis 8 and 5
13.7 ± 0.2 
(0–86.9) 0 ± 0 (0–0.2)
6.3 ± 0.2 
(0–97.3)
6.5 ± 0.2 
(0–99.7)
9.3 ± 0.2 
(0–89.2)
16.9 ± 0.3 
(0–100)
4.4 ± 0.1 
(0–51.7)
2.3 ± 0.1 
(0–41.0)





5 and 3 2.1 ± 0.7 (1.4–2.8) 0 ± 0 (0–0)
13.1 ± 0.6 
(12.5–13.7)
27.4 ± 5.8 
(21.6–33.3)
2.5 ± 1.1 
(1.4–3.7)
48.5 ± 2.8 
(45.7–51.3)
0.5 ± 0.1 
(0.4–0.7)
4.9 ± 1.4 
(3.5–6.2)
1.0 ± 0.4 
(0.5–1.4)
Gray matter 6 and 7 14.9 ± 2.8 (11.4–18.3) 0 ± 0 (0–0)
15.2 ± 1.0 
(13.9–16.3) 0 ± 0 (0–0)
24.0 ± 2.9 
(20.2–27.1)
0.2 ± 0.2 
(0.1–0.4)
24.1 ± 0.4 
(23.6–24.7)
15.6 ± 5.2 
(9.7–22.4)
6.0 ± 1.9 
(3.5–8.1)
White matter 4 and 7 3.2 ± 1.5 (1.3–5.0) 0 ± 0 (0–0)
14 ± 1.9 
(12.0–16.6) 0 ± 0 (0–0)
34.4 ± 3.8 
(29.7–39.1) 0 ± 0 (0–0)
19.6 ± 0.1 
(19.4–19.7)
28.7 ± 3.7 
(24.0–33.1) 0.1 ± 0.1 (0–0.2)
CSF 5 and 8 13.3 ± 2.0 (10.9–15.7) 0 ± 0 (0–0)
13.7 ± 1.5 
(12.5–15.9)
7.1 ± 1.2 
(6.1–8.8)
10.0 ± 1.5 
(8.9–12.1)
21.6 ± 4.7 
(18.1–28.3)
8.9 ± 0.8 
(7.9–9.9)
7.1 ± 1.5 
(5.6–9.2)
18.3 ± 3.8 
(13.2–22.0)
Necrosis 1 0 ± 0 (0–0) 76.8 ± 1.0 (75.7–77.8)
1.6 ± 1.5 
(0–3.1)
15.2 ± 6.0 
(9.2–21.3)
1.1 ± 1.0 
(0.1–2.1)
0.6 ± 0.1 
(0.5–0.7)
1.5 ± 1.5 
(0–3.0)
1.7 ± 1.5 
(0.2–3.2) 1.5 ± 1.5 (0–2.9)
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The pre-defined tissue types corresponding to each pattern are shown in Table 2. In normally appearing 
brain tissue, the dominant clusters were cluster 6 (mean ± standard deviation, 24.1 ± 0.4%) in gray matter and 
cluster 4 (34.4 ± 3.8%) in white matter. The dominant clusters in CSF and necrosis were different, although they 
were bright, exhibiting high T2 signal intensity with high baseline. The dominant cluster in CSF was cluster 5 
(21.6 ± 4.7%), wheres in necrosis it was cluster 1 (76.8 ± 1.0%). Using the autoencoder-derived representations, 
the differentiation of CEL tumors from other tissue types was 91.1% accurate in the training set and 94.6% 
accurate in the internal validation set.
Figure 3 shows the nine clustered representative temporal patterns and how the patterns were spatially 
mapped in the representative patients. The nine clusters of temporal patterns differed in terms of baseline signal, 
depth of signal decrease, slope of signal decrease and recovery, and percentage recovery. For example, clusters 
4 and cluster 6 represented normal brain tissue with intermediate baseline signal intensity and a small depth of 
signal decrease.
Dominant clusters of temporal patterns in brain tumor. The dominant clusters of temporal patterns 
for glioblastoma were cluster 5 (32.6%) and cluster 3 (26.7%), as shown in Fig. 4a. These patterns had an inter-
mediate baseline, acute slope of signal decrease, and a large depth of signal decrease. The relative recovery was 
small, and the pattern distribution was heterogeneous.
The dominant clusters for PCNSL were the same as for glioblastoma, namely cluster 5 (37.0%) and cluster 3 
(27.7%). However, the frequency of cluster 3 was slightly higher in PCNSL than in glioblastoma. Figure 4b shows 
the dominant clusters of temporal patterns for PCNSL, which had an intermediate baseline, less acute signal 
decrease slope, and small depth of signal decrease. The relative recovery was high. The cluster distribution was 
more homogeneous in PCNSL than in glioblastoma.
The dominant clusters for metastasis were cluster 8 (40.6%) and cluster 5 (16.9%), and the corresponding 
temporal patterns are shown in Fig. 4c. Metastasis was characterized by a high baseline and had the most acute 
signal decrease slope. It also showed a large depth of signal decrease, and the relative recovery was low. Compared 
with PCNSL, the cluster distribution for metastasis was heterogeneous.
Tumor differentiation and external validation. Table  3 summarizes the diagnostic performance 
results. Using the dominant clusters of time-signal intensity curves, the CNN distinguished PCNSL from glio-
blastoma in the training set with an AUC of 0.921 (95% confidence interval [CI] 0.860–0.951), sensitivity of 
93.6%, and specificity of 81.0%. On the internal validation set, the CNN distinguished PCNSL from glioblastoma 
with an AUC of 0.93 (95% CI 0.821–0.983), sensitivity of 85.7%, and specificity of 90.9%. External validation of 
the CNN gave an AUC of 0.89 (95% CI 0.75–0.97), sensitivity of 95.2%, and specificity of 76.5%.
Figure 3.  A demonstration of spatial mapping of tissue type clusters and decoded time-signal intensity 
curves from a glioblastoma patient. The graph on the right shows the nine representative tissue types that were 
clustered using autoencoder features and decoded time-signal intensity curves. The x-axis is time points (a total 
of 60 time points, 1.7 s for each time point) and the y-axis is the signal intensity normalized to the contralateral 
white matter. The resulting nine clusters differed in terms of baseline signal, depth of signal decrease, slopes of 
signal decrease and recovery, and relative recovery. The yellow lines show the mean time-signal intensity curves 
of each representative curve. The figure was drawn using Matlab (version R2017b, Mathworks, Natick, MA) and 
extra permission for drawing figures was not required.
7
Vol.:(0123456789)
Scientific Reports |        (2020) 10:21485  | https://doi.org/10.1038/s41598-020-78485-x
www.nature.com/scientificreports/
When distinguishing metastasis from glioblastoma, the CNN had an AUC of 0.89 (95% CI 0.83–0.94), sen-
sitivity of 81.6%, and specificity of 84.4% on the training set. Internal validation gave an AUC of 0.95 (95% 
CI 0.83–0.99), sensitivity of 90.0%, and specificity of 85.7%. There was no external validation set available for 
metastasis.
Figure 4.  Spatial distribution of clusters of decoded time-signal intensity curves in brain tumor. (a) Patterns 
were heterogeneously distributed in glioblastoma. Dominant clusters of time-signal intensity curves (from 
cluster 5 and 3) showed an acute signal decrease slope and small relative recovery. (b) The distribution of 
clusters was less heterogeneous in primary central nervous system lymphoma (PCNSL) than in glioblastoma. 
Dominant clusters (from cluster 5 and 3) showed a less acute signal decrease slope and high relative recovery. 
(c) The distribution of clusters was also heterogeneous in metastasis. Dominant clusters (from cluster 8) showed 
a large depth of signal decrease and extremely low signal recovery. The figure was drawn using Matlab (version 
R2017b, Mathworks, Natick, MA) and extra permission for drawing figures was not required.
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For distinguishing metastasis from PCNSL, the CNN had an AUC of 0.80 (95% CI 0.71–0.87), sensitivity of 
74.1%, and specificity of 81.6% on the training set. Internal validation gave an AUC of 0.90 (95% CI 0.75–0.98), 
sensitivity of 81.8%, and specificity of 90.0%. There was no external validation set available for metastasis.
The assignments of each tissue type in the external validation set are shown in Supplementary Table S1. The 
assignment of tissue types was similar to that of normally appearing brain tissue located in cluster 4 (44.0%), 
whereas the tumoral tissues were located in cluster 5 (49.5%) and cluster 3 (29.3%). In the external validation set, 
the accuracy of differentiating CEL tumors from other tissue types according to cluster frequencies was 86.7%.
Comparison to conventional rCBV approach. Clustering analysis based on autoencoder-derived tem-
poral patterns had significantly better diagnostic performance when distinguishing PCNSL from glioblastoma 
than the rCBV approach (AUC 0.79, 95% CI 0.65–0.90) (Delong’s test, P < 0.001). In the external validation 
set, cluster analysis and rCBV had similar diagnostic performance (AUC 0.92, 95% CI 0.88–0.98) (P = 0.56) 
(Table 3).
The clustering analysis of autoencoder-derived temporal patterns also had significantly better diagnostic 
performance than rCBV for distinguishing metastasis from glioblastoma (AUC 0.81, 95% CI 0.65–0.92; Delong’s 
test, P < 0.001) and metastasis from PCNSL (AUC 0.59, 95% CI 0.41–0.76; Delong’s test, P < 0.001).
Discussion
In this study, a clustering analysis of autoencoder-derived temporal pattern that used information from complex 
time-signal intensity curves in the whole brain highlighted how the spatial heterogeneity of DSC imaging can 
be used for tissue characterization. The high-dimensional information included in DSC MRI obtained from 
all voxels and patients was reduced into nine representative clusters of temporal patterns. These patterns were 
functionally clustered to separate tissue types and were 91% accurate when used to differentiate between tumor 
and non-tumor. The differentiation of glioblastoma from metastasis, which was difficult to be achieved using 
the scalar-based parameters of rCBV methods, was improved when it was based on the dominant clusters of 
temporal patterns. These dominant clusters offered high diagnostic performance during tumor diagnosis. Fur-
thermore, this autoencoder method does not require model-based calculation of the DSC signal and external 
validation. The autoencoder effectively learned the complex DSC time-signal intensity curves, and compared 
with other perfusion methods, provided additional information on intratumoral perfusion heterogeneity and 
generalizability across centers, which has clinical significance in perfusion analysis.
The autoencoder-derived temporal pattern enabled the use of comprehensive information in the signal-
intensity time curves of DSC MRI, including baseline signal intensity, slope and depth of signal decrease, and 
percentage recovery. Leakage-corrected rCBV reflects an early phase of information by using signal drop and 
 recovery7, while percentage signal  recovery23, derived from the ΔR2* curves obtained from DSC perfusion 
imaging, reflects a delayed phase of information. These information snapshots, as well as one-dimensional 
parameters, are affected by the complex interplay of technical (e.g., pulse sequence, contrast agent dose) and 
pathologic (e.g., vascular permeability, tumor cell volume fraction)  factors8, 13. For example, the accuracy of rCBV 
depends on acquisition parameters such as TE and flip  angle14. The calculation of leakage correction is software 
 dependent24, 25, and the percentage signal recovery is also influenced by contrast agent preload and pulse sequence 
 parameters8. Indeed, when we compared the average rCBV values, the rCBVs of glioblastoma were 5.52 ± 2.33 
(mean ± standard deviation) vs. 7.34 ± 1.51 in the internal and external validation sets, respectively. The average 
rCBV of PCNSL was 3.77 ± 1.52 vs. 3.38 ± 1.34 in the internal and external validation sets, respectively. The high 
diagnostic performance of rCBV for differentiating between glioblastoma and PCNSL comes from the higher 
Table 3.  Diagnostic performances of autoencoder-derived pattern analysis and conventional rCBV approach. 
rCBV relative cerebral blood volume, PCNSL primary central nervous system lymphoma.
Parameter AUC value (95% CI) Cutoff Sensitivity (%) Specificity (%)
Differentiation of glioblastoma from PCNSL
Internal validation set
 Autoencoder-derived pattern analysis 0.93 (0.82–0.98) NA 85.7 90.1
 rCBV 0.79 (0.65–0.90) 3.5 57.1 95.0
External validation set
 Autoencoder-derived pattern analysis 0.89 (0.75–0.97) NA 95.2 76.5
 rCBV 0.92 (0.88–0.98) 3.0 90.0 86.7
Differentiation of glioblastoma from metastasis
Internal validation set
 Autoencoder-derived pattern analysis 0.95 (0.83–0.99) NA 90.0 85.7
 rCBV 0.81 (0.65–0.92) 3.2 70.0 85.7
Differentiation of metastasis from PCNSL
Internal validation set
 Autoencoder-derived pattern analysis 0.90 (0.75–0.98) NA 81.8 90.0
 rCBV 0.59 (0.41–0.76) 3.5 45.4 80.0
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rCBV values in glioblastoma. The higher rCBV values may be a result of the shorter TE (30 ms) in the external 
validation set compared with the TE of 40 ms, which would increase the baseline signal and induce a large signal 
 drop26. These factors influencing the model-based assumptions are a barrier to the general use of DSC MRI. The 
autoencoder-derived temporal pattern used in this study did not require complex model-based assumptions, 
which might lead to broader use of the technique. Also, the method did not need correction based on center or 
scanner type, which illustrates its potential for use in multicenter DSC MRI temporal pattern analysis.
This method provides an effective way of learning from a large amount of DSC MRI data. Because a single 
DSC perfusion image can have approximately 3.2 × 105 time-signal intensity curves, achieving supervised learning 
in all voxels is challenging. Previous studies utilizing DSC perfusion imaging relied on either averaged time-signal 
intensity curves within a given  ROI27 or manually selected single or several voxels in the tissue of  interest28, 29. 
However, these methods do not accurately represent tumor heterogeneity and require discarding spatial infor-
mation included in DSC time-signal intensity data. The autoencoder-derived temporal pattern method used 
entire labeled tissues with a probability matching template, and the spatial mapping of autoencoder features 
captured relevant spatial information in the clustering method. Spatial heterogeneity is a hallmark of  cancer30. 
The visualization of clusters revealed such differences in tumors, e.g., glioblastoma exhibited more intratumoral 
heterogeneity than PCNSL. Quantifying heterogeneity in representative time-signal intensity patterns will be 
useful to the investigation of tumor biology.
The autoencoder learned temporal patterns that were subsequently used for supervised learning of tumor 
diagnosis. In the differentiation of glioblastoma from PCNSL, our method showed high diagnostic performance, 
with AUCs of 0.93 and 0.89 in the internal and external validation sets, respectively. Also, for distinguishing 
metastasis from glioblastoma, an AUC of 0.95 was shown in the internal validation. For differentiating metastasis 
from PCNSL, our method showed an AUC of 0.90 in the internal validation. Machine learning using quantified 
maps from diffusion-weighted or perfusion-weighted imaging has been applied to the differentiation of the above 
three  diseases31, 32, but our autoencoder approach has strengths in that it captures intratumoral heterogeneity 
by utilizing time-signal intensity curves. Furthermore, the diagnostic performance was high in our method 
compared with a maximum accuracy of 69.2%31 amongst three diseases. Glioblastoma and metastasis can be 
distinguished from PCNSL based on high rCBV and low percentage of signal recovery relative to the low rCBV 
and high percentage signal recovery seen in  PCNSL33. However, neither of these parameters are helpful distin-
guishing metastasis from glioblastoma, which remains inarguably one of the most difficult distinctions in clinical 
practice. Indeed, metastatic tumors showed distinct differences from glioblastoma and PCNSL in the dominant 
cluster, which had a very low relative signal recovery. Furthermore, PCNSL showed the most homogeneous clus-
ter distributions of temporal patterns, whereas metastasis showed vastly different clusters according to the varied 
cell types. Differentiating the primary tumors of PCNSL and glioblastoma from the secondary brain tumors of 
metastasis is an important task in neuro-oncology because treatment options differ  vastly34, 35. The performance 
of the autoencoder might benefit tumoral diagnoses based on differences in temporal patterns.
This study has several limitations. First, the diagnostic performance of the CNN dropped in the external 
validation, possibly as a result of overfitting. Although the external validation used a similar DSC acquisition 
based on the consensus  recommendation3 and standardized assessment of  rCBV2, the time-signal intensity curves 
can nonetheless be affected by technical differences. Thus, the curves might need to be further adjusted if the 
contrast agent preload and image acquisition protocols are very different. Second, there was no external valida-
tion for metastasis because DSC MRI is not commonly performed on patients with suspected brain metastases. 
Finally, tumors exhibited spatial heterogeneity although dominant clusters were selected to represent tumors. 
Further sophisticated method to explain entire spatial heterogeneity of DSC time-signal intensity will be needed 
in the future.
In conclusion, the clustering of autoencoder-derived temporal patterns provided information that was not 
otherwise accessible with rCBV perfusion methods and showed generalizability across different centers.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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